WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H465512
CAS#: 1917306-14-9
Description: JNJ-61803534 is a novel potent RORγt inverse agonist, selectively inhibiting RORγt-driven transcription versus closely-related family members, RORα and RORβ, also inhibiting IL-17A production in human CD4+ T cells under Th17 differentiation conditions, but not inhibiting IFNγ production under Th1 differentiation conditions, and having neither impact on in vitro differentiation of regulatory T cells (Treg), nor on the suppressive activity of natural Tregs.
Hodoodo Cat#: H465512
Name: JNJ-61803534
CAS#: 1917306-14-9
Chemical Formula: C23H23Cl2F6N3O4S
Exact Mass: 621.07
Molecular Weight: 622.404
Elemental Analysis: C, 44.38; H, 3.72; Cl, 11.39; F, 18.31; N, 6.75; O, 10.28; S, 5.15
Related CAS #: 1917306-14-9
Synonym: JNJ-61803534; JNJ 61803534; JNJ61803534;
IUPAC/Chemical Name: (R)-5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(2-methylpyrrolidine-1-carbonyl)thiazole-2-carboxamide
InChi Key: ZQHVEGQHOKDZEN-SNVBAGLBSA-N
InChi Code: InChI=1S/C23H23Cl2F6N3O4S/c1-10-5-4-8-34(10)19(36)15-16(39-18(33-15)17(35)32-9-20(2,3)37)11-6-7-12(14(25)13(11)24)21(38,22(26,27)28)23(29,30)31/h6-7,10,37-38H,4-5,8-9H2,1-3H3,(H,32,35)/t10-/m1/s1
SMILES Code: O=C(C1=NC(C(N2[C@H](C)CCC2)=O)=C(C3=CC=C(C(C(F)(F)F)(O)C(F)(F)F)C(Cl)=C3Cl)S1)NCC(C)(O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 622.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Xue X, De Leon-Tabaldo A, Luna-Roman R, Castro G, Albers M, Schoetens F, DePrimo S, Devineni D, Wilde T, Goldberg S, Hoffmann T, Fourie AM, Thurmond RL. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534. Sci Rep. 2021 May 26;11(1):11066. doi: 10.1038/s41598-021-90497-9. PMID: 34040108; PMCID: PMC8155022.